Short answer: A compounded dental anaesthetic gel delivers topical mucosal anaesthesia at strengths and combinations no commercial dental gel offers — for example, benzocaine 20% or lidocaine at concentrations above the standard commercial range. Clinical trials confirm that topical anaesthetic gels reduce injection pain and procedural discomfort on oral mucosa. A compounding pharmacy prepares the gel on a dentist’s or doctor’s prescription under Good Compounding Practice (GCP), as a non-sterile preparation for a named patient.
The evidence for topical anaesthetic gels in dental practice
Topical anaesthetic gels are widely used in dental practice to reduce the pain of needle injection and to anaesthetise oral mucosa before minor procedures. A randomised controlled trial comparing 20% benzocaine and 60% lidocaine gel for topical anaesthesia of oral mucosa demonstrated that both concentrations produce effective surface anaesthesia, with the higher-strength lidocaine gel achieving more rapid onset (Fukayama et al., Oral Surgery, Oral Medicine, Oral Pathology, 2002; PMID 12221381).
A randomised controlled trial of the efficacy of topical benzocaine in the maxilla confirmed that benzocaine gel reduces pain during dental injections compared with placebo (Rehman et al., Anesthesia Progress, 2019; PMID 30883233). A randomised controlled trial comparing a fast-acting and a traditional topical dental anaesthetic found measurable differences in onset time between formulations, highlighting that the choice of active and concentration affects clinical performance (DiMarco et al., Anesthesia Progress, 2016; PMID 27269661).
A randomised controlled trial comparing clove and benzocaine versus placebo as topical anesthetics demonstrated that benzocaine gel produces anaesthetic effects beyond placebo on oral mucosa (Alqareer et al., Journal of Dentistry, 2006; PMID 16530911).
Why compounding a dental anaesthetic gel matters
Commercial dental anaesthetic gels are typically available at fixed concentrations — most commonly benzocaine 20% or lidocaine-based preparations at standard strengths. When a dental practitioner needs a different concentration, a combination of actives in a single gel, or a vehicle suited to a specific application site, compounding is the formulation route.
A comparison of topical anesthetics (EMLA/Oraqix versus benzocaine) on pain experienced during palatal needle injection found that different anaesthetic formulations perform differently depending on the site and the procedure, supporting the rationale for having a range of concentrations and vehicles available (Al-Melh et al., Oral Surgery, Oral Medicine, Oral Pathology, 2007; PMID 17331753). A more recent split-mouth randomised clinical trial comparing a mucoadhesive patch against benzocaine gel for reducing injection pain confirmed that benzocaine gel remains a relevant comparator in dental anaesthesia research (Sahebalam et al., Oral and Maxillofacial Surgery, 2026; PMID 42625076).
Liposomal delivery for oral mucosal anaesthesia
Liposomal encapsulation has been explored as a delivery system for topical anaesthesia of the oral mucosa. A randomised controlled trial of a liposomal delivery system for topical anaesthesia of the palatal mucosa demonstrated that liposomal encapsulation of a local anaesthetic produced measurable anaesthetic effects on oral mucosa (Franz-Montan et al., British Journal of Oral & Maxillofacial Surgery, 2012; PMID 21106282). A separate study of liposome-encapsulated ropivacaine for intraoral topical anaesthesia confirmed that liposomal vehicles can deliver effective surface anaesthesia in the oral cavity (Franz-Montan et al., Oral Surgery, Oral Medicine, Oral Pathology, 2010; PMID 21112538).
These studies are relevant to compounding because they demonstrate that the vehicle — not just the active — determines how effectively the anaesthetic reaches the target tissue. A compounding pharmacy can prepare a dental anaesthetic gel in a vehicle the prescriber selects, including a liposomal vehicle where the prescriber’s clinical rationale supports it.
What a prescriber specifies for a compounded dental anaesthetic gel
- Active ingredient and concentration (e.g., lidocaine 5%, benzocaine 20%, or a combination)
- Dosage form: gel
- Vehicle preference (e.g., standard gel base or liposomal vehicle)
- Application site (e.g., palatal mucosa, gingival mucosa, intra-pocket)
- Named patient prescription
Safety considerations
The primary safety concern with topical anaesthetic gels is systemic absorption. Benzocaine, in particular, carries a risk of methaemoglobinaemia at higher concentrations, and the prescriber must consider the total dose applied, the application area, and the patient’s age and medical history. The concentration of the compounded gel, the amount applied, and the frequency of application must be specified on the prescription and communicated to the patient or dental staff.
For paediatric patients, the risk of methaemoglobinaemia from benzocaine is a specific concern, and prescribers should follow current regulatory guidance on benzocaine use in children. A compounded gel does not bypass these safety considerations — it is prepared to the prescriber’s specification, and the prescriber remains responsible for the clinical risk assessment.
Discussing a dental anaesthetic gel preparation with Lynnity
Lynnity prepares compounded dental anaesthetic gels as non-sterile preparations for a named patient on a dentist’s or doctor’s prescription, under Good Compounding Practice (GCP). The prescriber specifies the active, concentration, vehicle and application site; the pharmacy prepares to that specification. Where a clinic also requires a related topical anaesthetic preparation — for example, a compounded BLT cream (benzocaine, lidocaine, tetracaine) for surface anaesthesia on intact skin — the same prescription channel applies. Clinicians can include the formulation brief — vehicle preference, concentration rationale, excipient exclusions — alongside the prescription, so the pharmacy can assess compatibility and stability before preparation.
Frequently asked questions
What concentrations of anaesthetic can be compounded in a dental gel?
The concentration is specified by the prescriber. Common compounded concentrations include benzocaine 20% and lidocaine at various strengths, but the exact concentration depends on the clinical indication, the application site, and the patient’s safety profile. The pharmacy prepares the gel to the prescribed specification under GCP.
Can a dental anaesthetic gel be prepared in a liposomal vehicle?
Yes. Clinical trials have demonstrated that liposomal encapsulation of local anaesthetics produces effective surface anaesthesia on oral mucosa. A prescriber can specify a liposomal vehicle on the compounding prescription where the clinical rationale supports it.
Is a compounded dental anaesthetic gel safe for children?
Safety in paediatric patients depends on the active, concentration, application area and frequency. Benzocaine carries a risk of methaemoglobinaemia, and prescribers should follow current regulatory guidance. The compounded gel is prepared to the prescriber’s specification, and the prescriber remains responsible for the clinical risk assessment.
How does a compounded dental gel differ from a commercial product?
A commercial dental anaesthetic gel is manufactured at a fixed concentration and formulation. A compounded gel is prepared to the prescriber’s specification — which may include a different concentration, a combination of actives, or a specific vehicle — for a named patient. It is not a registered, mass-manufactured product.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632)
To discuss a patient-specific dental anaesthetic gel — at individualised strengths, in a standard or liposomal vehicle — consult Lynnity’s compounding pharmacists, including Lead Pharmacist Vitthia Rama Murti, RPh (RPh 15632), at the compounding facility in MWE Commercial Park, Kepong, Kuala Lumpur.